| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 4979.0 | 4921.0 | 3302.0 |
| Other income | -10.0 | -12.0 | -27.0 |
| Total income | 4969.0 | 4909.0 | 3275.0 |
| Profit before exceptional items & tax | 747.0 | 754.0 | 804.0 |
| Exceptional items | -10.0 | -21.0 | -13.0 |
| Profit before tax | 737.0 | 733.0 | 791.0 |
| Net profit | 534.0 | 566.0 | 591.0 |
| Operating margin | 14.8% | 14.9% | 24.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -9.60% |
|---|---|
| Net profit, quarter on quarter | -5.70% |
| Revenue, year on year | +50.80% |
| Operating profit, year on year | -8.90% |
| Operating profit, quarter on quarter | -1.20% |
BSE results filing, NSE: TORNTPHARM. Figures extracted from the filing.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,557.00
- Market cap
- ₹1,73,334 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 81.6×Sector 46.1×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Revenue grew 51% following the JB Chemicals merger, but underlying business shows integration headwinds.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Debt & Borrowing
Torrent Pharmaceuticals filed its security cover certificate as on 30-Sep-26 for listed NCDs, showing 141% market-value cover. Secured debt covered by the certificate stands at Rs 11,578.42 Crore.
Torrent Pharmaceuticals Management Change
Torrent Pharmaceuticals' Executive Director, Amal Kelshikar, has resigned from his position effective October 16, 2026.
Torrent Pharmaceuticals Credit Rating
India Ratings affirmed Torrent Pharmaceuticals' existing credit ratings and revised the outlook to positive. The company's commercial paper rating was also affirmed and assigned.
Torrent Pharmaceuticals Board Meeting Date
Torrent Pharmaceuticals will hold a board meeting on 23-Oct-26 to consider standalone audited and consolidated unaudited financial results for the quarter and half-year ended 30-Sep-26.
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals confirmed Chintan M. Trivedi as Company Secretary and Compliance Officer. KFin Technologies Limited remains the company's Registrar and Share Transfer Agent.